G protein coupled receptors (GPCRs) are attractive targets for pharmacological modulation due to their role in many medically-relevant biological processes. GPCR signaling however is quite complex because a single type of GPCR can be coupled to different types of G proteins and other proteins thereby activating several corresponding signal transduction cascades. Most of the GPCR-targeted drugs on the market today are from earlier days of drug discovery where the dampening of receptor signaling was blunt and all of the pathways controlled by a GPCR were affected by a GPCR-targeted drug. The renewed excitement in the field of GPCR drug discovery is due to technological progress which has enabled the collection of more structural data on GPCRs and is allowing study of receptors in different conformational states. This new information portends an era of more precise modulation of receptor signaling via discovery of compounds that can activate or inhibit only the signaling pathway of interest (ligand-biased signaling).
Cambridge Healthtech Institute’s back-to-back 9th Annual GPCR-Based Drug Discovery meeting and 2nd Annual GPCR-Targeted Therapeutics conferences cover advances that are not only illuminating GPCR structure and signaling complexities but also providing ways to translate the increased knowledge into realization of ‘precision’ drug discovery. 9th Annual GPCR-Based Drug Discovery will focus on structural aspects of GPCRs and new assays and technologies that are enabling discovery of biased ligands for GPCRs. 2nd Annual GPCR-Targeted Therapeutics will consist of case studies of lead compounds progressing in development and the pharmacological complexities that are encountered. The back-to-back day-and-a-half meetings are part of CHI’s three day, multi-meeting track event, Discovery on Target.
'GPCR-Based Drug Discovery' topics:
Updates on recently solved GPCR crystal structures
Fragment approaches for discovering GPCR-targeted compounds
Probing various conformational states of GPCRs
Assays for biased signaling (e.g. -- SPR-based screening)
PPI modulation of GPCR-complexes
New assays: BRET-based, live-cell assays, visualizing receptor complexes
Receptor trafficking, desensitization and internalization and implications for drug discovery Part 2:
Who should attend: Researchers, Scientists, Students, Post-docs, Professors, Group Leaders, Directors, Managers from Pharmaceutical companies, Biotechnology companies, Contract Research Organizations, Academia and Government working in fields such as Cell Biology, Biology, Molecular Pharmacology, Drug Discovery, High throughput Screening, Assay Development, GPCR screening, Signal Transduction, Neuroscience, CNS, Diabetes, Cardio-Metabolic Diseases, Inflammation, Pain, Translational Medicine, Structure Based Design, Computational Chemistry, Discovery Chemistry
If you are interested in speaking, please click here to submit a proposal.
The deadline for submission is March 28, 2014.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, please contact:
Anjani Shah, Ph.D.
Cambridge Healthtech Institute
T: (+1) 914-723-0255
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483